In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells

• Published in: Blood Vol. 118; no. 21; p. 2923
• Main Authors: Lawasut, Panisinee, Jacobs, Hannah M., Delmore, Jake E, Negri, Joseph, McMillin, Douglas W., Weisberg, Ellen L, Griffin, James D., Richardson, Paul G., Anderson, Kenneth C, Mitsiades, Constantine S.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 18.11.2011

Abstract 2923 Midostaurin (PKC412; Novartis Pharmaceuticals) is a multi-targeted kinase inhibitor currently being evaluated in clinical trials in acute myelogenous leukemia (AML), because of its potent activity in cells expressing mutant FLT3. Prior preclinical studies from our groups have shown tha...